Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL
4.3 PORTER'S FIVE FORCES MODEL
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET
5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.2 RESTRAINTS
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)
6.2.3 RISE IN PRODUCT RECALLS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE
6.4 CHALLENGES
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT
6.4.2 STRINGENT REGULATIONS
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)
7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 OPIOID DEPENDENCY MEDICATION
7.2.1.1 BUPRENORPHINE AND NALOXONE
7.2.1.2 BUPRENORPHINE
7.2.1.3 METHADONE
7.2.1.4 NALTREXONE
7.2.2 ALCOHOL USE DISORDER MEDICATIONS
7.2.2.1 NALTREXONE
7.2.2.2 DISULFIRAM
7.2.2.3 ACAMPROSATE
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION
7.2.3.1 NALOXONE
7.3 THERAPY
7.3.1 BEHAVIORAL THERAPY
7.3.2 EDUCATIONAL THERAPY
7.3.3 COUNSELLING
7.3.4 VOCATIONAL THERAPY
7.3.5 OTHERS
8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS
8.1 OVERVIEW
8.2 BUPRENORPHINE AND NALOXONE
8.3 NALTREXONE
8.4 BUPRENORPHINE
8.5 METHADONE
8.6 NALOXONE
8.7 DISULFIRAM
8.8 ACAMPROSATE
9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 SUBOXONE
9.3.2 VIVITROL
9.3.3 BUTRANS
9.3.4 ZUBSOLV
9.3.5 PROBUPHINE
9.3.6 OTHERS
10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 IMMEDIATE RELEASE
10.3 EXTENDED RELEASE
11 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SUBLINGUAL FILM
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 SOLUTION
11.3.2 SUSPENSION
11.4 OTHERS
12 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 TEENAGE
13 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER
13.1 OVERVIEW
13.2 REHABILITATION CLINICS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 HOMECARE
13.6 OTHERS
14 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 DIRECT TENDER
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 INDIVOR PLC (2021)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 VIATRIS INC (2021)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ALKERMES (2021)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PURDUE PHARMA L.P. (2021)
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 PFIZER (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 GLENMARK PHARMACEUTICAL INC (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 DR. REDDY’S LABORATORIES LTD (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ALVOGEN (2021)
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 AMNEAL PHARMACEUTICALS LLC (2021)
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 AMERICAN ADDICTION CENTERS (2021)
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 HIKMA PHARMACEUTICALS PLC (2021)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 LANNETT (2021)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 MALLINCKRODT (2021)
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 PINNACLE TREATMENT CENTERS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 RECOVERY CENTERS OF AMERICA
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 TAJ PHARMACEUTICALS LIMITED
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 TITAN PHARMACEUTICALS (2021)
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.S. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.S. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.S. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 U.S. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 U.S. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 69 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.S. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 72 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 73 U.S. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 74 U.S. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 75 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 CANADA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 CANADA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 CANADA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 CANADA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 CANADA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 85 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 86 CANADA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 87 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 88 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 CANADA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 CANADA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 92 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 MEXICO MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 MEXICO OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 MEXICO ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 MEXICO OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 MEXICO THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 101 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 102 MEXICO BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 103 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 104 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 105 MEXICO ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 MEXICO PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029
FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET
FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019
FIGURE 16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021
FIGURE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021
FIGURE 25 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021
FIGURE 29 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 34 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021
FIGURE 37 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021
FIGURE 41 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 49 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 50 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
